SAN DIEGO -- Patients with mantle cell lymphoma (MCL) and undetectable minimal residual disease (uMRD) after induction ...

The "sledgehammer-like treatment" of stem cell transplants had no benefit for most mantle cell lymphoma patients, according ...

The feud between Arcellx and Legend Biotech over their anti-BCMA CAR-T therapies for multiple myeloma is getting extra spicy ...

Stay updated on promising new treatments for Diffuse Large B-cell Lymphoma and B-cell acute lymphoblastic leukemia in this ...

The inMIND trial results have elevated expectations for Monjuvi's commercial success, but competition is on the horizon.

A simple change to the chemotherapy regimen for people with Hodgkin lymphoma could reduce the long-term health impacts that ...

A study in mice offers evidence that inhibiting EZH2 can enhance lymphoma immunogenicity and overcome CAR-T cell therapy resistance.

A haematologist shares insights into the challenges of the disease and the promise of emerging treatment options.

Adding tafasitamab to treatment with lenalidomide and rituximab improved progression-free survival in patients with relapsed or refractory follicular lymphoma.

Adding the humanized CD19-targeted monoclonal antibody tafasitamab (Monjuvi) to a backbone of lenalidomide (Revlimid) and ...

With a median follow-up of 14.1 months, adding tafasitamab to lenalidomide and rituximab reduced the risk of progression, ...

Jake, the airport therapy dog at Buffalo Niagara International, has died after battling lymphoma over the past 18 months.